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Abstract
In South Africa, the high prevalence of
familial hypercholesterolaemia (FH)
among Afrikaners, Jews, and Indians as a
result of founder genes is in striking
contrast to its reported virtual absence in
the black population in general. In this
study, the molecular basis of primary
hypercholesterolaemia was studied in 16
Africans diagnosed with FH. DNA analy-
sis using three screening methods resulted
in the identification of seven diVerent
mutations in the coding region of the low
density lipoprotein (LDLR) gene in 10 of
the patients analysed. These included a 6
bp deletion (GCGATG) accounting for
28% of defective alleles, and six point
mutations (D151H, R232W, R385Q,
E387K, P678L, and R793Q) detected in
single families. The Sotho patient with
missense mutation R232W was also het-
erozygous for a de novo splicing defect
313+1G→A. Several silent mutations/
polymorphisms were detected in the
LDLR and apolipoprotein B genes, includ-
ing a base change (g→t) at nucleotide
position −175 in the FP2 LDLR regulatory
element. This promoter variant was de-
tected at a significantly higher (p<0.05)
frequency in FH patients compared to
controls and occurred in cis withmutation
E387K in one family. Analysis of four
intragenic LDLR gene polymorphisms
showed that the same chromosomal back-
ground was identified at this locus in the
four FH patients with the 6 bp deletion.
Detection of the 6 bp deletion in Xhosa,
Pedi, and Tswana FH patients suggests
that it is an ancient mutation predating
tribal separation approximately 3000
years ago.
(J Med Genet 2000;37:514–519)
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Autosomal dominant hypercholesterolaemia
(ADH) is most commonly caused by mutations
in the low density lipoprotein receptor (LDLR)
gene causing familial hypercholesterolaemia
(FH), or in the apolipoprotein B (ApoB) gene
causing familial defective apo B (FDB).1 2
These biochemical defects result in the precipi-
tation of excess cholesterol and clinical charac-
teristics include tendon xanthomata and pre-
mature coronary heart disease (CHD). The
estimated incidence of both FH and FDB is
approximately 1 in 500 in most white popula-
tions.
In the Afrikaner population of South Africa,
the prevalence of FH has been increased to
approximately 1 in 70, as a consequence of a
founder eVect following the introduction of at
least three defective LDLR gene alleles by
European settlers.3–5 This is in striking contrast
to the apparently low prevalence of FH in the
black population, reported to have migrated
from central Africa to the south in three main
groups, the Ngunis (Xhosa, Tembu, Swazi, and
Zulu) along the east coast, the Sothos (South
Sotho, North Sotho/Pedi, West Sotho/Tswana)
who settled further west on the Transvaal high-
veld, and the Vendas living in the northern
Transvaal area.6 7 We suspect that FH is not
frequently recognised in Africans because of
altered clinical expression and not because of a
lower mutation prevalence compared to most
other populations. Previous studies have indi-
cated that the mutational mechanisms giving
rise to germline mutations are largely a
function of the local DNA sequence
environment.8–10
Since the situation in South Africa is ideal for
studies of underlying lipid related genetic
diVerences among population groups,11 we
attempted to identify black hypercholesterolae-
mics to determine the spectrum of mutations
in the promoter and coding region of the
LDLR gene and in exon 26 of the ApoB gene.
FDB has not previously been studied in the
South African black population, but was found
to be rare in other South African populations,
most likely because of a “negative” founder
eVect that diluted the frequency of the
common ApoB 3500 mutation in the immi-
grants relative to their parent populations.12
Subjects and methods
SUBJECTS
Blood samples were collected from 56 black
patients attending lipid clinics in South Africa,
after obtaining informed consent and ethical
approval from the regional Review Committees.
Details on clinical features and ethnicity were
provided by the referring clinicians. Sixteen
patients with a diagnosis of “classical” or “prob-
able” FH, including two FH homozygotes, were
selected for extensive mutation analysis for the
coding and promoter region of the LDLR gene
and exon 26 of the ApoB gene. Blood samples
were also obtained from 38 of their family
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members (table 1). Classical FH (12 probands)
was defined as the occurrence of pretreatment
total cholesterol (TC) >7 mmol/l, with the pres-
ence of tendon xanthomata or premature CHD
or both in the index case or a first degree relative.
Probable FH (four probands) was defined by
the same pretreatment cholesterol level and pri-
mary hypercholesterolaemia or premature CHD
or both in the family (table 1). DNA samples of
the 40 lipid clinic patients without the FH phe-
notype, but who had hyperlipidaemia or normal
lipid profiles in the presence of vascular disease,
were included for analysis of specific regions of
the LDLR gene. Ninety six people drawn from
the same population (19 Pedis, 21 Sothos, 27
Xhosas, and 29 Zulus) were sampled as
controls. TC, high density lipoprotein choles-
terol (HDLC), and triglyceride (TG) determi-
nations and extraction of genomic DNA were
performed using standard methods.13 Plasma
LDL cholesterol (LDLC) concentrations were
calculated with the Friedewald formula
(LDLC=TC−(HDL+TG/2.18)).14
MUTATION DETECTION
Heteroduplex single strand conformation poly-
morphism (HEX-SSCP) analysis was per-
formed in South Africa15 and denaturing
gradient gel electrophoresis (DGGE) in
Denmark16 and Scotland17 to screen polymer-
ase chain reaction (PCR) amplified genomic
DNA for mutations in the LDLR and ApoB
genes. For HEX-SSCP analysis, the exon spe-
cific primers described by Jensen et al18 were
used, while the promoter region of the LDLR
gene was amplified using primers 5'-
GAGGCAGAGAGGACAATGGC-3' and 5'-
CCACGTCATTTACAGCATTTCAATG-3'.
Base changes in the promoter region were
numbered according to Hobbs et al,19 after
adding an additional A within the AAAA
stretch preceding repeat 1, which is missing
from the published sequence.20 PCR products
showing aberrant electrophoresis patterns were
sequenced on both strands with a PCR
Product Sequencing kit (Amersham) or an
automated sequencer ABI 373A or both.
HAPLOTYPE ANALYSIS
Haplotype analysis using four LDLR gene
polymorphisms was performed according to
Theart et al.21 Microsatellite markers VWA31,
F1A1, and TH01 (Profiler kit, Applied Biosys-
tems) were used to test for biological consist-
ency in two families.
STATISTICAL ANALYSIS
Allele frequencies were determined by allele
counting. Testing for significance of heterogen-
eity in mutation frequencies among patient and
control groups was based on the chi-square
and Fisher’s exact tests.
Results
Extensive DNA screening of the LDLR gene in
16 black FH patients, using both the DGGE
and HEX-SSCP screening methods, showed
six missense mutations in individual families
and a 6 bp deletion in four probands (table 1).22
The deletion (FH Cape Town-1), previously
described in a Xhosa FH homozygote,23 and
missense mutations D151H and R385Q have
not (yet) been reported in other populations.
Haplotype SmaI+/StuI+/AvaII− was associ-
ated with the deletion in all three FH heterozy-
gotes and a homoallelic FH homozygote.
Screening of the coding region in DNA of the
four FH patients heterozygous for a base
change (g→t) at nucleotide position −175 of
the LDLR gene promoter resulted in the detec-
tion of a recycling deficient mutation E387K19
in the DNA of subject EF. Interestingly, this
Pedi proband was found to be extremely
heterogeneous at the DNA level, since a silent
C to T base change was furthermore detected
at nucleotide position 1104 in exon 8, in addi-
tion to two silent mutations in the ApoB gene.
The G to C change in the third base of codon
3540 (T3540T) and the T to C change in the
third base of codon 3552 (T3552T) in the
ApoB gene have previously been reported in
Table 1 Characteristics of African probands analysed for LDLR and apo B gene mutations
Index Ancestry Sex Age
TC TG HDL LDL
Clinical
LDLR gene
sequence changes
Apo B gene
sequence changes
Relatives
tested(mmol/l)‡
CM Xhosa F 52 8.5 2.7 1.5 5.8 CHD R793Q 0
MX Xhosa M 50 10.8 2.0 0.9 9.0 Arc, Xan −175g→t 0
AN Swazi F 58 10.1 0.9 1.3 8.4 Arc, Xan, CHD D151H 0
AS Swazi M 49 8.0 1.0 2.1 5.4 Arc, CHD P678L 0
AM* Swazi/Zulu F 56 8.3 1.5 1.9 5.7 Arc 11
CK† Zulu M 26 13.8 0.8 1.3 12.1 Arc, Xan −175g→t 1
SH Sotho M 33 12.7 2.2 1.2 10.5 Arc, Xan 313+1G→A; R232W 4
RK Sotho M 58 10.7 2.3 1.0 8.6 CHD R385Q 0
KN† Pedi F 32 14.9 0.8 1.4 13.1 Arc, Xan 6-bp del, 6-bp del 0
EF Pedi F 56 13.1 1.1 1.2 11.4 Arc, PVD, CHD E387K; −175g→t; C347C T3552T; T3540T 10
LP Pedi F 61 9.4 0.8 0.9 8.1 Arc, Xan 6-bp del 3
CN* Pedi F 57 7.4 2.6 0.9 5.3 Arc, PVD 6
RM* Pedi/Tswana F 54 10.8 0.4 1.3 9.3 Arc, ?Xan 3
LM* Tswana F 56 6.1 1.8 1.8 3.5 Arc, CHD −175g→t T3552T 0
RL Tswana F 30 9.3 0.8 1.7 7.2 Arc, Xan 6-bp del 0
CS Tswana F 47 7.9 0.7 1.7 5.9 Arc 6-bp del 0
The majority of mutations summarised in this table were included in a recent mutation update.22
Reference plasma cholesterol concentrations in the general black population are given in ref 24.
TC, total cholesterol; TG, triglycerides, HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; CHD, coronary heart disease; PVD,
peripheral vascular disease; Arc, arcus cornealis; Xan, xanthomata.
*Probable FH.
†Clinical FH homozygotes.
‡Pretreatment concentrations, except for proband LM for whom pretreatment levels were not available.
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Nigerian and African-American subjects,
respectively.17 One of the daughters of proband
EF (II.3 in fig 1) carried two copies of the silent
ApoB mutation at codon 3540. RFLP analysis
indicated that haplotype SmaI+/StuI+/AvaII−/
NcoI+ cosegregated with the −175t allele in the
family (fig 1). This chromosomal background
was also identified in two of the other probands
with the sequence substitution at −175 in the
LDLR promoter region, while haplotype
SmaI−/StuI+/AvaII+/NcoI+ was associated
with the t allele in the Tswana proband (LM),
who also carried the T3552T variant in the
ApoB gene.
In order to determine whether the two
mutations identified in each of probands EF
and SH occur in cis or in trans on their respec-
tive chromosomes, blood samples were ob-
tained from additional family members for
segregation analysis. Pedigree analysis in the
family of EF showed that mutation E387K and
the −175g→t variant occur on the same
chromosome (fig 1). All the family members
who inherited the 387K/−175t haplotype (I.1,
I.2, II.2, II.4, III.2, and III.5) had abnormally
high TC and LDLC levels. II.2, with a clinical
diagnosis of heterozygous FH, was homo-
zygous for the t allele at nucleotide position
−175. This implies that her deceased father
(husband of the index case) also carried the
−175g→t promoter variant, but in the absence
of mutation E387K. Her normocholesterolae-
mic son (III.1), as well as her brother, inherited
this paternal chromosome, the latter presenting
with a moderately raised TC value. The
proband’s son (II.1) and one of her daughters
(II.3) (confirmed by marker studies using
highly informative microsatellites) had moder-
ately raised plasma cholesterol concentrations
in the absence of either the promoter variant or
the exonic mutation, indicating that another
unknown factor contributes to the abnormal
lipid profile observed in this family. TC
concentrations were found to be very low in the
general black population (approximately 3
mmol/l) compared with other South African
groups.24 25
DNA screening of the 53 year old father of
proband CK, diagnosed with homozygous FH,
showed homozygosity for the t allele at
nucleotide position −175. His TC and LDLC
levels were 6.11 mmol/l and 4.29 mmol/l,
respectively, which is comparable to that of a
FH heterozygote. Plasma TG and HDLC con-
centrations were 1.49 mmol/l and 1.14 mmol/l,
respectively, and the only clinical feature
indicative of hyperlipidaemia in this obligate
FH heterozygote was corneal arcus.
HEX-SSCP analysis indicated that the splic-
ing defect identified in exon 3 represents a de
novo event in the family of SH, since it was not
present in any of his close relatives analysed.
Familial relationship was illustrated by trans-
mission of the exon 5 mutation (R232W) from
the father (72 years, TC 4.1 mmol/l), and was
further substantiated by marker studies using
three highly informative microsatellites (data
not shown). Mutation R232W was absent in
the normocholesterolaemic brother (30 years,
TC 3.5 mmol/l) and sister (42 years, TC 3.3
mmol/l) of the proband. Their mother, aged 62
years, presented with a TC level of 2.9 mmol/l.
It was therefore not possible to determine
whether the splice mutation occurred in cis in
the proband on the paternal chromosome
bearing mutation R232W, or in trans on the
normal maternal chromosome.
Subsequent DNA screening of 96 controls
from the general black population comprising
56 Ngunis (27 Xhosas, 29 Zulus) and 40 Sot-
hos (19 Pedis, 21 Sothos) resulted in the iden-
tification of six subjects (four Ngunis (one
Xhosa, three Zulus) and two Sothos (one Pedi,
one Sotho)) heterozygous (6%) for the −175t
allele. Although the number of patients ana-
lysed is small, the frequency of this allele
appeared to be higher within each tribal group
(2/6 Ngunis and 2/10 Sothos with FH)
Figure 1 Pedigree of proband EF (arrow) clinically diagnosed with heterozygous FH.Clinical, biochemical, and genetic
data are provided for people for whom DNA samples were available. Those with raised plasma cholesterol levels are
indicated by dark (mutation positive for E387K) and shaded symbols. The presence (+) or absence (−) of LDLR gene
mutations and recognition sites for SmaI, StuI, AvaII, and NcoI are indicated.
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compared to the controls (4/56 Ngunis and
2/40 Sothos). An overall statistically significant
diVerence (p<0.05) was observed between the
presence of the rare t allele in the general black
population (0.03) compared to its frequency of
0.13 in the patients diagnosed with classical or
probable FH (÷2=5.916, 1 df, p=0.0149). We
furthermore detected five carriers of the
−175g→t polymorphism among 40 lipid clinic
patients without the FH phenotype (13%),
showing an intermediate allele frequency of
0.06. This was not significantly diVerent from
the frequencies observed in the FH (÷2=1.326,
1 df, p=0.249) or control (÷2=1.474, 1 df,
p=0.224) groups. Variant −175g→t was also
detected in 1/47 DNA samples of controls from
the Venda tribe studied by Ehrenborg et al,25
which was absent in more than 300 whites
screened.26
Discussion
Numerous low density lipoprotein receptor
(LDLR) gene mutations (>600) have been
identified in FH patients, but genetic data on
black African populations are rare.19 22 23 27 A
striking finding is that a 6 bp deletion
predominates in a small number (5/18) of FH
patients (this study)19 23 28 identified in the
South African black population, where this
lipid disorder is thought to be rare. This
deletion in exon 2 removes an aspartic acid and
a glycine from the first cysteine rich ligand
binding repeat of LDLR, and impairs its trans-
port but not lipoprotein binding in
fibroblasts.23 Frequent detection of a deleteri-
ous mutation can be the result of consanguin-
ity, recurrent mutational events, genetic drift,
founder gene eVect, multiple introduction of
the mutation into a population, or heterozygote
advantage.
The 6 bp deletion identified originally in a
homoallelic Xhosa FH homozygote,23 and now
also in a homozygous Pedi and three FH
heterozygotes (Pedi and two Tswanas) on the
same haplotype, have not (yet) been reported
in other populations. These findings largely
exclude the likelihood of a recurrent muta-
tional event because of slipped mispairing or
multiple entries of the deletion mutation into
the black population. Detection of the deletion
in diVerent tribes suggests that it originated in
Africa approximately 3000 years ago before
tribal separation.29 Although FH patients with
the deletion may therefore be distantly related,
family ties cannot at present explain its
relatively high prevalence among black FH
patients. The apparently low prevalence of FH
in South African blacks and the large popula-
tion size furthermore argue against a founder
eVect. It is, however, possible that the deletion
mutation was propagated and inherited within
a small group of people who later evolved sepa-
rately into diVerent African tribes. Another
plausible explanation is that this deleterious
deletion mutation may be associated with a
selective advantage in Africa. Already in 1990
Hobbs et al,30 noted that the presence of several
founder mutations in diVerent South African
population groups4 31 may be indicative of a
Darwinian selection that favours the hetero-
zygous state in this region of the world. Since
the most likely selective agent in Africa would
be infectious diseases, the finding that LDLR
deficient mice are protected against lethal
endotoxaemia and severe gram negative
infections32 supports the likelihood of such an
evolutionary selection mechanism conferring a
survival advantage. In addition to binding and
inactivating endotoxin, lipoproteins also bind
certain viruses and inhibit their infectivity.33
Although the family data presented in this
study show that the −175g→t polymorphism
residing in a cis acting element in the LDLR
promoter34 does not cause the FH phenotype in
aVected subjects, further studies are warranted
to investigate the likelihood that this variant
may influence disease expression. The possi-
bility that the significantly higher frequency of
the −175g→t promoter polymorphism in
South African black FH patients compared to
controls (p<0.05) is caused by linkage disequi-
librium with another downstream mutation
causing the FH phenotype was excluded by
haplotype studies showing that the rare t allele
was associated with diVerent LDLR haplo-
types. This allele furthermore cosegregated
with missense mutation E387K in one family.
These diVerent chromosomal backgrounds
may be the result of recombination events,
reflecting the age of the −175g→t variant.
Compared to whites, blacks are considered
older in evolutionary terms35 and can therefore
be expected to have accumulated variation over
longer times. It is possible that the −175g→t
polymorphism did not spread to other parts of
the world, thereby explaining its apparent
absence in whites (this study).18 36 The African
origin of the −175g→t variant was confirmed
by detection of the rare t allele at a low
frequency in control DNA samples obtained
from Nigerians and African-Americans.26
African-Americans originated mostly from the
western African coast and arrived in North
America between the 16th and 19th centuries.
One Sotho proband was heterozygous for a
known splicing defect in intron 3
(313+1G→A) and for the R232W mutation in
exon 5. In all the patients with mutation
313+1G→A studied to date, the splicing defect
is associated with a clinical picture of severe
hypercholesterolaemia and early CHD.37 38
Patient SH had a TC concentration of 13
mmol/l, but it is uncertain whether this high
level is solely because of the 313+1G→A
mutation or whether there is an additional
eVect of the downstream R232W mutation.
Family studies could not rule out the possi-
bility of a double mutation, but showed that the
splicing defect is the consequence of a de novo
mutation. None of the family members of SH
were hypercholesterolaemic, including his 72
year old father (LDLC 1.9 mmol/l), who was
heterozygous for mutation R232W. This find-
ing indicates that R232W does not aVect
LDLR function or, alternatively, that clinical
expression of this missense mutation is altered
by other genetic/environmental factors.
Although the missense mutations identified
have not been characterised further, they are
likely contributors to the FH phenotype in our
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patient sample, since all the codon changes
involve conserved amino acids and were not
detected in the normal population. Screening
for mutations causing FDB16 17 39 resulted in
the identification of two silent mutations,
T3540T and T3552T (data not shown), previ-
ously described in a Nigerian and African-
American subject, respectively.17 Failure to
identify disease related mutations in all the
patients studied may be because of limitations
imposed by the screening techniques used,
clinical misdiagnosis of FH, or mutations in
other genes causing the ADH phenotype.40 41
Both the Zulu and Pedi patients clinically
diagnosed with homozygous FH presented
with relatively low pretreatment TC levels (<15
mmol/l) for this severe condition1 and neither
have yet suVered from CHD. The relatively
mild expression of homozygous FH in these
subjects largely precludes an estimation of the
prevalence of heterozygous FH in the South
African black population based on the preva-
lence of homozygous FH. Raised plasma chol-
esterol levels causing FH in a family frequently
remain undetected until the occurrence of cor-
onary events or clinical signs indicative of FH is
observed in one or more family members. This
may particularly be the case in the South Afri-
can black population, as hypercholesterolae-
mics with lipid profiles compatible with the
diagnosis of heterozygous FH frequently lack
xanthomata characteristic of this condition
(this study).42 None of the FH heterozygotes
with the relatively severe 6 bp deletion in exon
223 presented with CHD. These findings
provide evidence that FH is probably under-
diagnosed in the South African black popula-
tion, most likely as a consequence of altered
expression of FH related mutations. This may
be the result of interaction with other genetic
and environmental factors, including a prudent
diet.11 Data provided by us and others43–45
therefore suggest that clinical/biochemical cri-
teria for the diagnosis of FH need to be diVer-
ent by country/population and that DNA
methods may assist in making a definitive
disease diagnosis.
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